Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Google Inc (GOOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Google Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Google Inc trades at $355.5 (market cap $4.35T). The key difference: Google Inc is far larger — about 109× Alnylam Pharmaceuticals, Inc.'s market cap, and Google Inc pays a 0.25% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GOOG | |
|---|---|---|
Market Cap | $39.89B | $4.35T |
Sector | Health | Technology |
52-Week High | $491.22 | $399.06 |
52-Week Low | $278.09 | $181.31 |
Enterprise Value | $38.15B | $4.31T |
Volume | — | 1,511,127 |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Alphabet (GOOG) trades at $355.03, down 0.34% on the day, with a neutral technical signal and strong fundamental performance. The stock shows robust revenue growth, with 2025 revenue reaching $402.84 billion and net income of $132.17 billion, supported by consistent earnings beats. Analyst consensus is overwhelmingly bullish with an 86.84% buy rating and a $457.50 price target, indicating significant upside potential from current levels.
The outlook for GOOG remains positive driven by AI investments and cloud growth, but risks include regulatory scrutiny and high valuation multiples. With strong cash flow generation and institutional support, the stock presents a compelling opportunity for growth-oriented investors, though market volatility and competitive pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
